$LKFT News

Lakefront Biotherapeutics NV 2026 Q1 - Results - Earnings Call Presentation

Galapagos NV (GLPG) Q1 2026 Earnings Call Transcript

Galapagos Q1 EPS US$0.25 Beats US$(1.27) Estimate, Sales US$7.589M Miss US$16.040M Estimate

Galapagos Announces Nomination of Gino Santini to its Board of Directors

Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders’ Meetings

Galapagos Intends To Appoint Gino Santini As Board Chair, Effective April 28

Assessing Galapagos (ENXTAM:GLPG) Valuation After Mixed Returns And A Modest Undervaluation Estimate

Galapagos Creates New Subscription Right Plan

Galapagos NV Board Creates 1.75M Subscription Rights Under New Subscription Right Plan

Galapagos Appoints Tania Philipp as Chief Human Resources Officer

Galapagos FY25: Profits Not Built On Product

RBC Capital Maintains Sector Perform on Galapagos, Raises Price Target to $33

Galapagos NV (GLPG) Q4 2025 Earnings Call Transcript

Earnings Breakdown: Galapagos Q4

Galapagos Q4 EPS $13.82 increased from $0.30, Sales $1.049B increased from $80.575M

A Peek at Galapagos's Future Earnings

Third Arc Bio Announces $52M Series A Extension to Expand Oncology and Immunology & Inflammation Portfolio

Galapagos (ENXTAM:GLPG) Valuation Check After Mixed Results And Ongoing Net Loss

Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities

Galapagos NV shares are trading higher. The company announced its intention to wind down its cell therapy activities following a comprehensive strategic review and sale process.